Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918187 | 1.00 | MTNR1A (0.49) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3928924 | 0.89 | MTNR1A (0.51) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3928926 | 0.89 | MTNR1A (0.51) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3930770 | 0.84 | MTNR1A (0.52) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3930766 | 0.84 | MTNR1A (0.52) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL10985186 | 0.81 | HTR2A (0.45) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL10985779 | 0.81 | HTR2A (0.45) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3929101 | 0.79 | CYP2D6 (0.50) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3929104 | 0.79 | CYP2D6 (0.50) | MTNR1ACYP2D6MTNR1BADRA2AADRA1A | |
| SCHEMBL3923362 | 0.77 | CYP1A2 (0.47) | ADRA2AADRA1ACYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1934159-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | MTNR1A 1491/4885CYP2D6 82/4885MTNR1B 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.